Skip to main content

Expert Consensus Recommendations for Risk-Adapted Management of Myeloproliferative Neoplasms 2026

In brief

Korean experts update risk-based treatment guidance for three myeloproliferative diseases

New Korean consensus recommendations cover polycythemia vera, essential thrombocythemia and myelofibrosis, incorporating refined diagnosis, broader molecular risk assessment and newer treatments. They outline options from aspirin and blood removal to stem cell transplantation, with guidance for pregnancy and advanced disease. These are evidence-informed recommendations, not trial results, and their role is to support individualized care in Korean practice.

Journal
Cancer research and treatment (Q1)
Published
18 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1c)
Authors
Sung-Eun Lee, Seug Yun Yoon, Haerim Chung, Jong-Ho Won, Chul Won Jung, Chul Won Choi, et al.
PMID
43057127
DOI
10.4143/crt.2026.0979

Why clinicians should know about it

  • Picked for Hematology (top studies of the week, 22 November 2026): Updated risk-adapted guidance for MPN treatment and transplantation

Abstract

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are clonal hematopoietic disorders, with ET representing the most common Philadelphia chromosome-negative MPN in Korea. Since the previous Korean MPN guideline was published in 2020, the field has advanced considerably: diagnostic criteria have been further refined, the molecular landscape informing prognosis and treatment decisions has broadened, and new agents have become available. These developments have created a need to update the previous recommendations for the Korean clinical context. These expert consensus recommendations were developed by the Korean Society of Hematology MPN working Party to provide practical, evidence-informed recommendations for the risk-adapted management of PV, ET, and MF in Korean clinical practice. Recommendations are based on a comprehensive review of current international guidelines, including those of the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN), alongside emerging data from Korean and Asian patient populations. They address risk stratification frameworks, treatment goals evolving from hematologic response toward molecular response, and therapeutic options including phlebotomy, aspirin, cytoreductive agents, and allogeneic hematopoietic stem cell transplantation. Special clinical situations, including MPN in pregnancy and advanced-phase disease (accelerated and blast phase), are also addressed. These recommendations aim to support individualized, biology-informed treatment decisions, and to facilitate the integration of evolving therapeutic strategies into routine Korean hematology practice.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.